...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Biochemical markers in early diagnosis and management of systemic amyloidoses
【24h】

Biochemical markers in early diagnosis and management of systemic amyloidoses

机译:早期诊断和管理系统淀粉蛋白的生化标志物

获取原文
获取原文并翻译 | 示例

摘要

Systemic amyloid diseases are characterized by widespread protein deposition as amyloid fibrils. Precise diagnostic framing is the prerequisite for a correct management of patients. This complex process is achieved through a series of steps, which include detection of the tissue amyloid deposits, identification of the amyloid type, demonstration of the amyloidogenic precursor, and evaluation of organ dysfunction/damage. Laboratory medicine plays a central role in the diagnosis and management of systemic amyloidoses, through the quantification of the amyloidogenic precursor and evaluation of end-organ damage using biomarkers.
机译:全身淀粉样蛋白疾病的特征在于广泛的蛋白质沉积作为淀粉样蛋白原纤维。 精确的诊断框架是正确管理患者的先决条件。 该复杂方法通过一系列步骤来实现,其包括检测组织淀粉样沉积物,鉴定淀粉样蛋白类型,淀粉样蛋白前体的演示以及器官功能障碍/损伤的评估。 实验室药物在系统淀粉样膜的诊断和管理中发挥着核心作用,通过定量淀粉样淀粉样品前体和使用生物标志物的终末器官损伤的评价。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号